newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Reuters
Desmoda is a proprietary, patented oral formulation of desmopressin for treating central diabetes insipidus.
Desmoda is a newly approved oral formulation of desmopressin for central diabetes insipidus.
KEY POINTS
Desmoda addresses dosing challenges that doctors face in stabilizing water and sodium levels.
Eton Pharmaceuticals expects Desmoda's annual peak sales to reach $30 million to $50 million.
Desmoda is specifically aimed at treating arginine vasopressin deficiency, a rare hormone disorder.
The drug, Desmoda, is a proprietary, patented oral formulation of desmopressin for treating central diabetes insipidus, or arginine vasopressin deficiency (AVP-D), a rare disorder in which the body lacks the hormone that regulates water balance, causing excessive urination and thirst.
Sign up here.
The approval helps address a long‑standing challenge in managing the condition, where doctors must carefully adjust dosing to keep water levels stable and prevent dangerous shifts in sodium, especially in children.
Eton expects Desmoda to generate annual peak sales in the range of $30 million to $50 million.
Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona